Advertisement

European Journal of Clinical Pharmacology

, Volume 71, Issue 7, pp 801–810 | Cite as

A review on colistin nephrotoxicity

  • Atefeh Ordooei Javan
  • Shervin Shokouhi
  • Zahra Sahraei
Review Article

Abstract

Purpose

Colistin is an antibiotic that was introduced many years ago and was withdrawn because of its nephrotoxicity. Nowadays, reemergence of this antibiotic for multi-drug resistant Gram-negative infections, and a new high dosing regimen recommendation increases concern about its nephrotoxicity. This review attempts to give a view on colistin nephrotoxicity, its prevalence especially in high doses, the mechanism of injury, risk factors, and prevention of this kidney injury.

Method

The data collection was done in PubMed, Scopus and Cochrane databases. The keywords for search terms were “colistin”, “nephrotoxicity”, “toxicity”, “renal failure”, “high dose”, and “risk factor”. Randomized clinical trials and prospective or retrospective observational animal and human studies were included. In all, 60 articles have been reviewed.

Result and conclusion

Colistin is a nephrotoxic antibiotic; a worldwide increase in nosocomial infections has led to an increase in its usage. Nephrotoxicity is the concerning adverse effect of this drug. The mechanism of nephrotoxicity is via an increase in tubular epithelial cell membrane permeability, which results in cation, anion and water influx leading to cell swelling and cell lysis. There are also some oxidative and inflammatory pathways that seem to be involved in colistin nephrotoxicity. Risk factors of colistin nephrotoxicity can be categorized as dose and duration of colistin therapy, co-administration of other nephrotoxic drugs, and patient-related factors such as age, sex, hypoalbuminemia, hyperbilirubinemia, underlying disease and severity of patient illness.

Keywords

Colistin Nephrotoxicity Adverse effect Risk factor Incidence 

References

  1. 1.
    Falagas ME, Kasiakou SK, Saravolatz LD (2005) Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 40(9):1333–1341PubMedCrossRefGoogle Scholar
  2. 2.
    Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, Paterson DL (2006) Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 6(9):589–601PubMedCrossRefGoogle Scholar
  3. 3.
    Nation RL, Li J (2009) Colistin in the 21st century. Curr Opin Infect Dis 22(6):535PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Lim LM, Ly N, Anderson D, Yang JC, Macander L, Jarkowski A, Forrest A, Bulitta JB, Tsuji BT (2010) Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing. Pharmacother J Human Pharmacol Drug Ther 30(12):1279–1291CrossRefGoogle Scholar
  5. 5.
    John E, Bennett RD, Blaser MJ (2015) Polymyxins (Polymyxin B and Colistin). In: Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. 8 edn. Elsevier Saunders, Canada, pp 549–555Google Scholar
  6. 6.
    Florescu DF, Qiu F, McCartan MA, Mindru C, Fey PD, Kalil A (2012) What is the efficacy and safety of colistin for the treatment of ventilator-associated pneumonia? A systematic review and meta-regression. Clin Infect Dis 54(5):670–680PubMedCrossRefGoogle Scholar
  7. 7.
    Bergen PJ, Li J, Rayner CR, Nation RL (2006) Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob Agents Chemother 50(6):1953–1958PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Mendes CAC, Burdmann EA (2009) Polymyxins: review with emphasis on nephrotoxicity. Rev Assoc Med Bras 55(6):752–759PubMedCrossRefGoogle Scholar
  9. 9.
    Michalopoulos AS, Falagas ME (2011) Colistin: recent data on pharmacodynamics properties and clinical efficacy in critically ill patients. Ann Intensive Care 1(1):1–6CrossRefGoogle Scholar
  10. 10.
    Plachouras D, Karvanen M, Friberg L, Papadomichelakis E, Antoniadou A, Tsangaris I, Karaiskos I, Poulakou G, Kontopidou F, Armaganidis A (2009) Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother 53(8):3430–3436PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Hartzell JD, Neff R, Ake J, Howard R, Olson S, Paolino K, Vishnepolsky M, Weintrob A, Wortmann G (2009) Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis 48(12):1724–1728PubMedCrossRefGoogle Scholar
  12. 12.
    DeRyke CA, Crawford AJ, Uddin N, Wallace MR (2010) Colistin dosing and nephrotoxicity in a large community teaching hospital. Antimicrob Agents Chemother 54(10):4503–4505PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Paul M, Bishara J, Levcovich A, Chowers M, Goldberg E, Singer P, Lev S, Leon P, Raskin M, Yahav D (2010) Effectiveness and safety of colistin: prospective comparative cohort study. J Antimicrob Chemother 65(5):1019–1027PubMedCrossRefGoogle Scholar
  14. 14.
    Markou N, Apostolakos H, Koumoudiou C, Athanasiou M, Koutsoukou A, Alamanos I, Gregorakos L (2003) Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients. Crit Care 7(5):R78PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Pintado V, San Miguel LG, Grill F, Mejía B, Cobo J, Fortún J, Martín-Dávila P, Moreno S (2008) Intravenous colistin sulphomethate sodium for therapy of infections due to multidrug-resistant gram-negative bacteria. J Infect 56(3):185–190PubMedCrossRefGoogle Scholar
  16. 16.
    Betrosian AP, Frantzeskaki F, Xanthaki A, Douzinas EE (2008) Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii  ventilator-associated pneumonia. J Infect 56(6):432–436PubMedCrossRefGoogle Scholar
  17. 17.
    Dalfino L, Puntillo F, Mosca A, Monno R, Spada ML, Coppolecchia S, Miragliotta G, Bruno F, Brienza N (2012) High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study. Clin Infect Dis 54(12):1720–1726PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Tuon FF, Rigatto MH, Lopes CK, Kamei LK, Rocha JL, Zavascki AP (2014) Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium. Int J Antimicrob Agents 43(4):349–352PubMedCrossRefGoogle Scholar
  19. 19.
    Pogue JM, Lee J, Marchaim D, Yee V, Zhao JJ, Chopra T, Lephart P, Kaye KS (2011) Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis 53(9):879–884PubMedCrossRefGoogle Scholar
  20. 20.
    Rocco M, Montini L, Alessandri E, Venditti M, Laderchi A, De Pascale G, Raponi G, Vitale M, Pietropaoli P, Antonelli M (2013) Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: a retrospective cohort study. Crit Care 17:R174PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    Sorlí L, Luque S, Grau S, Berenguer N, Segura C, Montero MM, Álvarez-Lerma F, Knobel H, Benito N, Horcajada JP (2013) Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study. BMC Infect Dis 13(1):1–9CrossRefGoogle Scholar
  22. 22.
    Kalin G, Alp E, Coskun R, Demiraslan H, Gündogan K, Doganay M (2012) Use of high-dose IV and aerosolized colistin for the treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia: do we really need this treatment? J Infect Chemother 18(6):872–877PubMedCrossRefGoogle Scholar
  23. 23.
    Duraković N, Radojčić V, Boban A, Mrsić M, Sertić D, Serventi-Seiwerth R, Nemet D, Labar B (2011) Efficacy and safety of colistin in the treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in patients with hematologic malignancy: a matched pair analysis. Intern Med (Tokyo, Japan) 50(9):1009–1013CrossRefGoogle Scholar
  24. 24.
    Kallel H, Bahloul M, Hergafi L, Akrout M, Ketata W, Chelly H, Hamida CB, Rekik N, Hammami A, Bouaziz M (2006) Colistin as a salvage therapy for nosocomial infections caused by multidrug-resistant bacteria in the ICU. Int J Antimicrob Agents 28(4):366–369PubMedCrossRefGoogle Scholar
  25. 25.
    Luque S, Grau S, Valle M, Sorlí L, Horcajada JP, Segura C, Álvarez-Lerma F (2013) Differences in pharmacokinetics and pharmacodynamics of colistimethate sodium (CMS) and colistin between three different CMS dosage regimens in a critically ill patient infected by a multidrug-resistant < i > Acinetobacter baumannii</i> Int J Antimicrob Agents 42(2):178–181PubMedCrossRefGoogle Scholar
  26. 26.
    Imberti R, Cusato M, Villani P, Carnevale L, Iotti GA, Langer M, Regazzi M (2010) Steady-state pharmacokinetics and BAL concentration of colistin in critically ill patients after IV colistin methanesulfonate administration. Chest J 138(6):1333–1339CrossRefGoogle Scholar
  27. 27.
    Cheng C-Y, Sheng W-H, Wang J-T, Chen Y-C, Chang S-C (2010) Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug-resistant Gram-negative bacterial infections. Int J Antimicrob Agents 35(3):297–300PubMedCrossRefGoogle Scholar
  28. 28.
    Roberts JA, Lipman J (2012) Editorial commentary: closing the loop—a colistin clinical study to confirm dosing recommendations from PK/PD modeling. Clin Infect Dis 54(12):1727–1729PubMedCrossRefGoogle Scholar
  29. 29.
    Li J, Nation RL, Milne RW, Turnidge JD, Coulthard K (2005) Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int J Antimicrob Agents 25(1):11–25PubMedCrossRefGoogle Scholar
  30. 30.
    Zavascki AP, Goldani LZ, Li J, Nation RL (2007) Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. J Antimicrob Chemother 60(6):1206–1215PubMedCrossRefGoogle Scholar
  31. 31.
    Falagas ME, Kasiakou SK (2006) Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care 10(1):R27PubMedCentralPubMedCrossRefGoogle Scholar
  32. 32.
    Spapen H, Jacobs R, Van Gorp V, Troubleyn J, Honoré PM (2011) Renal and neurological side effects of colistin in critically ill patients. Ann Intensive Care 1(1):1–7CrossRefGoogle Scholar
  33. 33.
    Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez F, Barrero-Almodovar A, Garcia-Garmendia J, Bernabeu-Wittell M, Gallego-Lara S, Madrazo-Osuna J (2003) Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 36(9):1111–1118PubMedCrossRefGoogle Scholar
  34. 34.
    Kim J, Lee K-H, Yoo S, Pai H (2009) Clinical characteristics and risk factors of colistin-induced nephrotoxicity. Int J Antimicrob Agents 34(5):434–438PubMedCrossRefGoogle Scholar
  35. 35.
    Kofteridis DP, Alexopoulou C, Valachis A, Maraki S, Dimopoulou D, Georgopoulos D, Samonis G (2010) Aerosolized plus intravenous colistin versus intravenous colistin alone for the treatment of ventilator-associated pneumonia: a matched case–control study. Clin Infect Dis 51(11):1238–1244PubMedCrossRefGoogle Scholar
  36. 36.
    Linden PK, Kusne S, Coley K, Fontes P, Kramer DJ, Paterson D (2003) Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa. Clin Infect Dis 37(11):e154–e160PubMedCrossRefGoogle Scholar
  37. 37.
    Linden PK, Paterson DL (2006) Parenteral and inhaled colistin for treatment of ventilator-associated pneumonia. Clin Infect Dis 43(Supplement 2):S89–S94PubMedCrossRefGoogle Scholar
  38. 38.
    Honoré PM, Jacobs R, Joannes-Boyau O, Lochy S, Boer W, De Waele E, Van Gorp V, De Regt J, Collin V, Spapen HD (2014) Continuous renal replacement therapy-related strategies to avoid colistin toxicity: a clinically orientated review. Blood Purif 37(4):291–295PubMedCrossRefGoogle Scholar
  39. 39.
    Falagas ME, Fragoulis KN, Kasiakou SK, Sermaidis GJ, Michalopoulos A (2005) Nephrotoxicity of intravenous colistin: a prospective evaluation. Int J Antimicrob Agents 26(6):504–507PubMedCrossRefGoogle Scholar
  40. 40.
    Katz R (1963) Renal and possibly hepatic toxicity from coly-mycin. Report of a case. Med Ann Dist Columbia 32:408PubMedGoogle Scholar
  41. 41.
    Ozkan G, Ulusoy S, Orem A, Alkanat M, Mungan S, Yulug E, Yucesan FB (2013) How does colistin-induced nephropathy develop and can it be treated? Antimicrob Agents Chemother 57(8):3463–3469PubMedCentralPubMedCrossRefGoogle Scholar
  42. 42.
    Ko H, Jeon M, Choo E, Lee E, Kim T, Jun J-B, Gil H-W (2010) Early acute kidney injury is a risk factor that predicts mortality in patients treated with colistin. Nephron Clin Pract 117(3):c284–c288PubMedCrossRefGoogle Scholar
  43. 43.
    Rattanaumpawan P, Ungprasert P, Thamlikitkul V (2011) Risk factors for colistin-associated nephrotoxicity. J Infect 62(2):187–190PubMedCrossRefGoogle Scholar
  44. 44.
    Kwon J-A, Lee JE, Huh W, Peck KR, Kim Y-G, Kim DJ, Oh HY (2010) Predictors of acute kidney injury associated with intravenous colistin treatment. Int J Antimicrob Agents 35(5):473–477PubMedCrossRefGoogle Scholar
  45. 45.
    Doshi NM, Mount KL, Murphy CV (2011) Nephrotoxicity associated with intravenous colistin in critically ill patients. Pharmacother J Human Pharmacol Drug Ther 31(12):1257–1264CrossRefGoogle Scholar
  46. 46.
    Kift EV, Maartens G, Bamford C (2014) Systematic review of the evidence for rational dosing of colistin. SAMJ: South African Med J 104(3):183–186CrossRefGoogle Scholar
  47. 47.
    Garonzik S, Li J, Thamlikitkul V, Paterson D, Shoham S, Jacob J, Silveira F, Forrest A, Nation R (2011) Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 55(7):3284–3294PubMedCentralPubMedCrossRefGoogle Scholar
  48. 48.
    Shavit L, Manilov R, Wiener-Well Y, Algur N, Slotki I (2013) Urinary neutrophil gelatinase-associated lipocalin for early detection of acute kidney injury in geriatric patients with urinary tract infection treated by colistin. Clin Nephrol 80(6):405–416PubMedCrossRefGoogle Scholar
  49. 49.
    Han WK, Bonventre JV (2004) Biologic markers for the early detection of acute kidney injury. Curr Opin Crit Care 10(6):476–482PubMedCrossRefGoogle Scholar
  50. 50.
    Ghlissi Z, Hakim A, Mnif H, Ayadi FM, Zeghal K, Rebai T, Sahnoun Z (2013) Evaluation of colistin nephrotoxicity administered at different doses in the rat model. Ren Fail 35(8):1130–1135PubMedCrossRefGoogle Scholar
  51. 51.
    Soni SS, Ronco C, Katz N, Cruz DN (2009) Early diagnosis of acute kidney injury: the promise of novel biomarkers. Blood Purif 28(3):165–174PubMedCrossRefGoogle Scholar
  52. 52.
    Keirstead ND, Wagoner MP, Bentley P, Blais M, Brown C, Cheatham L, Ciaccio P, Dragan Y, Ferguson D, Fikes J (2014) Early prediction of polymyxin-induced nephrotoxicity with next-generation urinary kidney injury biomarkers. Toxicol Sci 137(2):278–291PubMedCrossRefGoogle Scholar
  53. 53.
  54. 54.
    Ozyilmaz E, Ebinc FA, Derici U, Gulbahar O, Goktas G, Elmas C, Oguzulgen IK, Sindel S (2011) Could nephrotoxicity due to colistin be ameliorated with the use of N-acetylcysteine? Intensive Care Med 37(1):141–146PubMedCrossRefGoogle Scholar
  55. 55.
    Yousef JM, Chen G, Hill PA, Nation RL, Li J (2011) Melatonin attenuates colistin-induced nephrotoxicity in rats. Antimicrob Agents Chemother 55(9):4044–4049PubMedCentralPubMedCrossRefGoogle Scholar
  56. 56.
    Yousef JM, Chen G, Hill PA, Nation RL, Li J (2011) Ascorbic acid protects against the nephrotoxicity and apoptosis caused by colistin and affects its pharmacokinetics. J Antimicrob Chemotherapy:dkr483Google Scholar
  57. 57.
    Ghlissi Z, Hakim A, Sila A, Mnif H, Zeghal K, Rebai T, Bougatef A, Sahnoun Z (2014) Evaluation of efficacy of natural astaxanthin and vitamin E in prevention of colistin-induced nephrotoxicity in the rat model. Environ Toxicol Pharmacol 37(3):960–966PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Atefeh Ordooei Javan
    • 1
  • Shervin Shokouhi
    • 2
  • Zahra Sahraei
    • 1
  1. 1.Department of Clinical Pharmacy, School of PharmacyShahid Beheshti University of Medical SciencesTehranIran
  2. 2.Department of Infectious Disease, Loghman HospitalShahid Beheshti University of Medical SciencesTehranIran

Personalised recommendations